莫纳利珠单抗(Monalizumab) - 药物靶点：NKG2A_在研适应症：局部晚期非小细胞肺癌，不可切除的非小细胞肺癌，转移性头颈部鳞状细胞癌_专利_临床

概要

基本信息

药物类型

单克隆抗体

别名

ANTI-NKG2A、IPH-22、IPH-2201

+ [6]

靶点

NKG2A

作用方式

拮抗剂

作用机制

NKG2A拮抗剂(killer cell lectin like receptor C1 antagonists)

治疗领域

肿瘤呼吸系统疾病泌尿生殖系统疾病

在研适应症

局部晚期非小细胞肺癌不可切除的非小细胞肺癌转移性头颈部鳞状细胞癌+ [4]

非在研适应症

食管腺癌宫颈鳞状细胞癌慢性淋巴细胞白血病+ [13]

原研机构

在研机构

非在研机构-

权益机构

MedImmune Pharma BV

Innate Pharma SA

Novo Nordisk A/S

+ [1]

最高研发阶段临床3期

首次获批日期-

最高研发阶段(中国)临床3期

特殊审评-

登录后查看时间轴

结构/序列

Sequence Code 10109327H

来源: *****

Sequence Code 10109367L

来源: *****

关联

24

项与莫纳利珠单抗相关的临床试验

NCT07146230

/ Not yet recruiting临床2期IIT

The Selective Personalized Radio-Immunotherapy for Locally Advanced NSCLC Trial 2 (SPRINT 2)

This is a randomized trial evaluating the efficacy and safety of sequential dual-agent immunotherapy and risk-adapted radiotherapy for patients with locally advanced non-small cell lung cancer (NSCLC) with a PD-L1 tumor proportion score of at least 50%. Participants will be randomized between two dual-agent immunotherapy regimens: durvalumab + monalizumab versus durvalumab + oleclumab.

开始日期2026-03-01

申办/合作机构

Montefiore Medical Center

[+1]

NCT06769126

/ Recruiting临床2期IIT

PRISM: PRecIsion in SCLC Via a Multicohort Study: Randomized Phase II Studies Evaluating Maintenance Durvalumab With or Without Biomarker-Directed Therapy for Extensive Stage Small Cell Lung Cancer (ES-SCLC)

This phase II trial tests how well biomarker tests on patients tumor tissue works in selecting personalized treatments for patients with extensive stage small cell lung cancer (ES-SCLC). Biomarker tests look for certain features in cancer cells that may give doctors more information about what is driving cancer and how to treat it. Based on the biomarker test results, study doctors can determine the subtype of ES-SCLC that study treatments can target. This study also tests different types of maintenance treatment for ES-SCLC with drugs durvalumab, saruparib, ceralasertib or monalizumab. Maintenance treatment is given after initial treatment and is given to help keep the cancer under control and prevent it from getting worse. Immunotherapy with monoclonal antibodies, such as durvalumab and monalizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Saruparib is a PARP inhibitor. PARP is a protein that helps repair damaged deoxyribonucleic acid (DNA). Blocking PARP may prevent cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. Ceralasertib may stop the growth of tumor cells and may kill them by blocking some of the enzymes needed for tumor cell growth. Giving biomarker selected personalized maintenance treatment with durvalumab, saruparib, ceralasertib or monalizumab may work better in treating patients with ES-SCLC.

开始日期2025-11-06

申办/合作机构

SWOG

[+1]

NCT06503614

/ Recruiting临床2期IIT

ENHANCE (Elevated NKG2A and HLA-E Amplify NK/CD8 Checkpoint Engagers): A Phase 2 Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer

This is a phase 2 open-label two cohort study of durvalumab plus monalizumab in patients with BCG-unresponsive or BCG-exposed CIS NMIBC. Arm A will enroll 43 participants who have cancer in situ (CIS) with or without high grade papillary urothelial cancer. Arm B will enroll 17 participants who do not have cancer in situ (CIS) but do have high grade papillary urothelial cancer. Eligible patients will be enrolled to receive up to 13 cycles of monthly combination of monalizumab and durvalumab. Both monalizumab and durvalumab will be administered intravenously (IV) every 28 days.

开始日期2025-02-24

申办/合作机构

Hoosier Cancer Research Network

[+3]

100 项与莫纳利珠单抗相关的临床结果

登录后查看更多信息

100 项与莫纳利珠单抗相关的转化医学

登录后查看更多信息

100 项与莫纳利珠单抗相关的专利（医药）

登录后查看更多信息

30

项与莫纳利珠单抗相关的文献（医药）

2026-02-01·CPT-Pharmacometrics & Systems Pharmacology

Stochastic Gates for Covariate Selection in Population Pharmacokinetics Modeling

Article

作者: Dearden, Richard ; Gibbs, Megan ; Zhou, Diansong ; Kekic, Marija ; Tang, Weifeng ; Nowojewski, Andrzej ; Olabode, Damilola ; Wang, Wenjuan ; Stepanov, Oleg ; Traynor, Carlos ; Richardson, Sam

ABSTRACT:

Covariate selection in population pharmacokinetics modeling is essential for understanding interindividual variability in drug response and optimizing dosing. Traditional stepwise covariate modeling is often time‐consuming, compared to the new machine learning alternatives. This study investigates the use of neural networks with stochastic gates for automated covariate selection, aiming to efficiently identify relevant covariates while penalizing excessive covariate inclusion. On various synthetic datasets, the approach demonstrated robustness in detecting important covariates, overcoming challenges such as high correlations, low covariate frequencies, high interindividual variability, and complex covariate dependencies. In real clinical data from a monalizumab study, the method successfully identified covariates that matched those found by experts. However, for tixagevimab/cilgavimab, it identified a superset of covariates, indicating a potential need for further pruning. This machine learning‐based method enhances the covariate preselection process in population pharmacokinetics model development, offering significant time savings and improving efficiency even under challenging scenarios.

2026-01-06·CLINICAL AND EXPERIMENTAL IMMUNOLOGY

CD40L and IL-4 lymph node-associated signals protect B cells from rituximab-induced ADCC via KIR and NKG2A

Article

作者: Blunt, Matthew D ; Sayegh, Souraya ; Graham, Lara V ; Foxall, Russell B ; Cragg, Mark S ; Khakoo, Salim I ; Ashton-Key, Margaret ; Leandro, Maria ; Reddy, Venkat R

Abstract:

Autoreactive B cells that remain in lymphatic tissue after anti-CD20 antibody therapy are considered a major contributing factor to relapse in patients with autoimmune diseases. Natural killer (NK) cells contribute to the depletion of autoreactive B cells by anti-CD20 antibodies via antibody-dependent cellular cytotoxicity (ADCC). However, the impact of germinal centre–associated signals CD40 ligand (CD40L) and interleukin-4 (IL-4) on ADCC was unknown. This study used a combination of flow cytometry, immunohistochemistry, and ex vivo functional assays using peripheral blood mononuclear cells to investigate how CD40L and IL-4 affect NK cell–B cell interactions. CD40L and IL-4 significantly upregulate human leukocyte antigen (HLA)-E and total HLA Class I expression on the surface of B cells from healthy donors, as well as patients with rheumatoid arthritis and systemic lupus erythematosus. The upregulation of HLA-E and total HLA functions to inhibit B-cell depletion by NK cell–mediated ADCC induced by rituximab via NKG2A and killer cell immunoglobulin-like receptors (KIR). Moreover, B cells that have differentiated through the germinal centre have higher expression of HLA-E and total HLA compared with naive B cells and are more resistant to depletion by rituximab. In accordance with this, blockade of NKG2A and inhibitory KIRs by monalizumab and lirilumab, respectively, increased antibody-dependent cellular cytotoxicity against autologous B cells in vitro. Overall, this study identifies a novel mechanism of resistance of B cells to NK cell cytotoxicity and indicates that blockade of the HLA-E:NKG2A and HLA:KIR checkpoint axes could be beneficial for improving B-cell depletion in patients with autoimmune diseases.

2025-08-01·NATURE MEDICINE

Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trial

Article

作者: McGrath, Lara ; Insa, Amelia ; Shim, Byoung Yong ; He, Yun ; Cascone, Tina ; Bielska, Agata A ; Egenod, Thomas ; Provencio Pulla, Mariano ; Forde, Patrick M ; Livi, Lorenzo ; Grenga, Italia ; Kim, Dong-Wan ; Garcia Campelo, Maria Rosario ; Guisier, Florian ; Bylicki, Olivier ; Dowson, Adam ; Bennouna, Jaafar ; Corre, Romain ; Spicer, Jonathan ; Liberman, Moishe ; Metro, Giulio ; Bonanno, Laura ; Yohannes, Alula R ; Kumar, Rakesh ; Kar, Gozde

Abstract:

In the phase II NeoCOAST-2 platform study, 202 patients with untreated, resectable stage IIA–IIIB non-small-cell lung cancer (NSCLC) were randomized to receive neoadjuvant durvalumab plus platinum-doublet chemotherapy with oleclumab, a CD73 inhibitor (Arm 1), or with monalizumab, a NKG2A inhibitor (Arm 2), or neoadjuvant durvalumab plus single-agent platinum chemotherapy with the TROP-2 antibody–drug conjugate (ADC) datopotamab deruxtecan (Arm 4), followed by surgical resection and adjuvant durvalumab with oleclumab or monalizumab (Arms 1 and 2) or durvalumab alone (Arm 4). Primary endpoints were pathological complete response (pCR) rate and safety; secondary endpoints included feasibility of surgery and major pathological response (mPR) rate. In the modified intention-to-treat population (n = 198; Arm 1, n = 74; Arm 2, n = 70; Arm 4, n = 54), pCR rates were 20.3% (15/74; 95% CI, 11.8–31.2), 25.7% (18/70; 95% CI, 16.0–37.6) and 35.2% (19/54; 95% CI, 22.7–49.4), and mPR rates were 41.9% (31/74; 95% CI, 30.5–53.9), 50.0% (35/70; 95% CI, 37.8–62.2) and 63.0% (34/54; 95% CI, 48.7–75.7) in arms 1, 2, and 4, respectively. In the safety population, 69/74 (93.2%), 66/71 (93.0%), and 51/54 (94.4%) patients underwent surgery, respectively. Overall, grade ≥3 treatment-related adverse events occurred in 27/74 (36.5%), 29/71 (40.8%) and 11/54 (20.4%) patients, respectively. In NeoCOAST-2, the first neoadjuvant trial examining an ADC plus chemo-immunotherapy in resectable NSCLC, pCR rates were highest in the datopotamab-deruxtecan-containing arm, warranting further investigation in larger trials of ADCs and checkpoint inhibition in the neoadjuvant setting. ClinicalTrials.gov identifier: NCT05061550.

155

项与莫纳利珠单抗相关的新闻（医药）

2026-04-03

·BioSpace

Innate Pharma to Participate in the Kempen Life Sciences Conference

MARSEILLE, France--(BUSINESS WIRE)-- #Biotech --Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today announced that members of its executive team will participate in one-on-one investor meetings at the following conference: Kempen Life Sciences Conference Dates: April 15 –16, 2026 Location: Amsterdam, Netherlands About Innate Pharma Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Leveraging its expertise on antibody-engineering and innovative target identification, Innate Pharma is developing innovative and differentiated next-generation antibody therapeutics. Innate Pharma is advancing a portfolio of differentiated potential first and/or best-in-class assets, focused on areas of high unmet medical need, including IPH4502, a differentiated Nectin-4 ADC developed in solid tumors, lacutamab, an anti-KIR3DL2 antibody developed in cutaneous T cell lymphomas and peripheral T cell lymphomas, and monalizumab, an anti-NKG2A antibody developed in collaboration with AstraZeneca in non-small cell lung cancer. Innate Pharma has established collaborations with leading biopharmaceutical companies, including Sanofi and AstraZeneca, as well as renowned academic and research institutions, to advance innovation in immuno-oncology. Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US. Learn more about Innate Pharma at and follow us on LinkedIn and X . Information about Innate Pharma shares ISIN code Ticker code LEI FR0010331421 Euronext: IPH Nasdaq: IPHA 9695002Y8420ZB8HJE29 Disclaimer on forward-looking information and risk factors For a discussion of risks and uncertainties, please refer to the Risk Factors (“Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority (“AMF”), which is available on the AMF website or on Innate Pharma’s website ( ), and public filings and reports filed with the U.S. Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 20-F for the year ended December 31, 2025, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public by the Company. References to the Company’s website and the AMF website are included for information only and the content contained therein, or that can be accessed through them, are not incorporated by reference into, and do not constitute a part of, this press release. This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country. Contacts For additional information, please contact: I nvestors & Media Relations I nnate Pharma Stéphanie Cornen stephanie.cornen@innate-pharma.fr Investor Relations investors@innate-pharma.fr Media communication@innate-pharma.fr

免疫疗法临床研究

2026-04-02

·BioSpace

Innate Pharma Files Its 2025 Universal Registration Document (Document D’enregistrement Universel) and 2025 Form 20-f Annual Report

MARSEILLE, France--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced the filing of its 2025 Universal Registration Document ( Document d’enregistrement universel ) for the year ending December 31, 2025 with the French market authority “Autorité des Marchés Financiers” (“ AMF ”) on April 1 st , 2026. It can be downloaded (in French) on the Company’s website and on the AMF’s website . The following documents are incorporated into the Universal Registration Document: the annual financial report, the annual management report, the corporate governance report provided for under Article L. 225-37 of the French Commercial Code, the report of Statutory Auditors. The Company also announced today the filing of its Form 20-F annual report for the year ending December 31, 2025 with the United States Securities and Exchange Commission (“ SEC ”) on April 1 st , 2026. It can be also be accessed on the Company’s website and on the SEC’s website . About Innate Pharma Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Leveraging its expertise on antibody-engineering and innovative target identification, Innate Pharma is developing innovative and differentiated next-generation antibody therapeutics. Innate Pharma is advancing a portfolio of differentiated potential first and/or best-in-class assets, focused on areas of high unmet medical need, including IPH4502, a differentiated Nectin-4 ADC developed in solid tumors, lacutamab, an anti-KIR3DL2 antibody developed in cutaneous T cell lymphomas and peripheral T cell lymphomas, and monalizumab, an anti-NKG2A antibody developed in collaboration with AstraZeneca in non-small cell lung cancer. Innate Pharma has established collaborations with leading biopharmaceutical companies, including Sanofi and AstraZeneca, as well as renowned academic and research institutions, to advance innovation in immuno-oncology. Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US. Learn more about Innate Pharma at and follow us on LinkedIn and X . Information about Innate Pharma shares ISIN code Ticker code LEI FR0010331421 Euronext: IPH Nasdaq: IPHA 9695002Y8420ZB8HJE29 Disclaimer on forward-looking information and risk factors For a discussion of risks and uncertainties, please refer to the Risk Factors (“Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority (“AMF”), which is available on the AMF website or on Innate Pharma’s website ( ), and public filings and reports filed with the U.S. Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 20-F for the year ended December 31, 2025, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public by the Company. References to the Company’s website and the AMF website are included for information only and the content contained therein, or that can be accessed through them, are not incorporated by reference into, and do not constitute a part of, this press release. This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country. Contacts investors & Media Relations Innate Pharma Stéphanie Cornen stephanie.cornen@innate-pharma.fr Investor Relations investors@innate-pharma.fr Media communication@innate-pharma.fr

免疫疗法临床研究

2026-03-26

·药时空

砍掉 NK 项目，Innate 管线大瘦身聚焦核心

摘要：法国免疫疗法企业 Innate Pharma 正式终止四特异性 NK 细胞衔接器 IPH6501 的1/2期临床试验，这是公司持续推进管线精简的关键动作。结合此前 30% 的裁员调整、与赛诺菲合作项目的优先级下调，这家深耕 NK 细胞疗法的 biotech，正彻底告别广撒网模式，把资源集中到最具商业化潜力的核心品种，也映照出全球中小创新药企 “做减法、求生存” 的现实选择。突然终止：NK 衔接器项目止步临床阶段就在去年 11 月，Innate 还在按计划推进 IPH6501 的全球临床，准备在美国、澳大利亚和法国招募近 200 例 B 细胞非霍奇金淋巴瘤患者，这款依托公司 ANKET 平台的四特异性 NK 细胞衔接器，一度是公司血液瘤管线的重点在研产品，剂量爬坡阶段也已顺利完成。但在最新发布的 2025 年全年财报里，公司直接宣布终止这项研究，给出的理由很明确 —— 管线战略优先级调整。官方只提到，临床数据会在今年合适的时间点公布，项目本身不会再往前走。对一家以 NK 细胞免疫疗法为核心标签的企业来说，砍掉自家平台孵化的核心项目，谈不上技术失利，更像是算完长期账后的果断取舍。战略聚焦：裁员瘦身，锚定三大核心资产 Innate 的管线收缩，早有伏笔。去年年中，公司就启动了大规模战略重组，裁掉 30% 的员工，明确要把资金和人力投向 “最高价值资产”，当时 IPH6501 就没被列入核心清单，命运其实已经定下。如今公司的临床管线，已经清晰聚焦到三个品种上。IPH4502 是公司当下力推的 Nectin-4 靶向 ADC，CEO 在公开信息里提到，这款药在多线治疗失败的实体瘤患者中看到了早期疗效，即便对用过安斯泰来 Padcev 的尿路上皮癌患者也有效果，被寄予同类最佳的期待。另外两个核心品种，一个是即将进入 Ⅲ 期的皮肤癌药物 lacutamab，另一个是和阿斯利康合作、正在开展非小细胞肺癌 Ⅲ 期研究的 monalizumab，后者的临床数据读出，被看作公司今年最重要的价值节点。从平台扩张到单品攻坚，Innate 的转型思路一目了然。合作降温：赛诺菲再退 NK 项目，赛道理性回归管线精简的同时，Innate 和赛诺菲的长期合作也出现了调整。两家公司 2016 年就围绕 NK 细胞衔接器达成合作，如今赛诺菲把第二个合作项目 —— 靶向 BCMA 的三功能 NK 细胞衔接器 IPH6401 列为低优先级，只是保留了后续开发和商业化的权利。往前追溯，去年 4 月，赛诺菲已经归还过一个 CD123 靶点的 NK 项目。大药企接连退回合作品种，不是否定 NK 细胞疗法的方向，而是整个赛道从狂热布局转向理性筛选。没有明确临床优势、商业化路径模糊的早期项目，正在被快速出清。对失去部分合作资金支持的 Innate 来说，更没有余力维持宽泛的管线布局。行业观察：biotech 瘦身，是取舍更是生存 Innate 的选择，放在当下全球 biotech 的环境里，一点都不意外。前几年创新药赛道热的时候，平台型技术备受追捧，多特异性分子、新型免疫靶点扎堆推进，很多中小药企习惯了多点布局。但融资环境收紧、研发成本高企、监管审批趋严，让 “广撒网” 变得越来越难以为继。与其在多个早期项目上消耗现金流，不如集中资源把 1-2 个品种做到临床关键节点，做出差异化数据，才能拿到市场和合作伙伴的认可。IPH6501 的终止，本质上是创新药企回归商业常识 —— 管线的价值不在数量，而在能真正落地、解决未满足需求的潜力。甩掉非核心包袱的 Innate，接下来要靠三大核心品种兑现价值。而它的瘦身路径，也给不少还在管线拥挤中挣扎的中小 biotech，提供了一个很现实的参考：学会取舍，才能活得更久。参考来源：https://www.fiercebiotech.com/biotech/innate-ends-work-nk-cell-engager-phase-12-trial-part-ongoing-pipeline-refocus 识别微信二维码，可添加药时空小编请注明：姓名+研究方向！

100 项与莫纳利珠单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	莫纳利珠单抗	-	DB12824

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
局部晚期非小细胞肺癌	临床3期	美国	AstraZeneca PLC	2022-02-07
局部晚期非小细胞肺癌	临床3期	中国	AstraZeneca PLC	2022-02-07
局部晚期非小细胞肺癌	临床3期	日本	AstraZeneca PLC	2022-02-07
局部晚期非小细胞肺癌	临床3期	澳大利亚	AstraZeneca PLC	2022-02-07
局部晚期非小细胞肺癌	临床3期	巴西	AstraZeneca PLC	2022-02-07
局部晚期非小细胞肺癌	临床3期	加拿大	AstraZeneca PLC	2022-02-07
局部晚期非小细胞肺癌	临床3期	哥伦比亚	AstraZeneca PLC	2022-02-07
局部晚期非小细胞肺癌	临床3期	法国	AstraZeneca PLC	2022-02-07
局部晚期非小细胞肺癌	临床3期	德国	AstraZeneca PLC	2022-02-07
局部晚期非小细胞肺癌	临床3期	意大利	AstraZeneca PLC	2022-02-07

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03801902 (NRG-LU004, CTgov)	临床1期	复发性非小细胞肺癌 \| 不可切除的非小细胞肺癌 \| 局部晚期非小细胞肺癌	26	Accelerated Hypofractionated Radiation Therapy+Durvalumab (Arm I (CLOSED) (Durvalumab and ACRT))	鑰艱餘觸鏇憲艱鑰鏇艱 = 蓋鏇鹽蓋鹽製鏇淵糧鏇夢窪鬱積選蓋獵壓構製 (積獵膚膚窪鑰齋壓蓋廠, 齋醖齋鑰鹹鹹襯遞衊觸 ~ 願鬱蓋鏇鹹鹹鬱夢獵淵) 更多	-	2025-06-19
				Magnetic Resonance Imaging of the Brain+Durvalumab (Arm II (CLOSED) (Durvalumab and Standard RT))	鑰艱餘觸鏇憲艱鑰鏇艱 = 鑰鬱衊鏇簾網遞憲顧壓夢窪鬱積選蓋獵壓構製 (積獵膚膚窪鑰齋壓蓋廠, 艱製糧齋夢製鬱窪願夢 ~ 齋網壓糧糧顧顧衊壓鹽) 更多
NCT03822351 (COAST, ASCO2024) 人工标引	临床2期	不可切除的非小细胞肺癌	189	durvalumab	願範蓋觸鬱蓋願廠構壓(繭觸蓋糧糧觸遞鬱壓鹹) = 顧夢膚壓鏇壓繭醖遞鹹窪獵鹽製襯衊鹹築鹽夢 (壓廠繭廠壓壓淵選壓壓, 14.3 ~ 35.9) 更多	积极	2024-05-24
				durvalumab+oleclumab	願範蓋觸鬱蓋願廠構壓(繭觸蓋糧糧觸遞鬱壓鹹) = 遞醖積網鏇觸構壓構獵窪獵鹽製襯衊鹹築鹽夢 (壓廠繭廠壓壓淵選壓壓, 23.1 ~ 48.4) 更多
NCT03794544 (NeoCOAST, AACR2024) 人工标引	临床2期	可切除非小细胞肺癌新辅助	47	durvalumab	網鏇構願積觸廠積醖構(衊願簾鑰壓鏇鹹壓糧積) = Percent CD73+ TC and B cell abundance was higher in patients with MPR vs those without MPR in the durva + ole arm, but not in the durva monotherapy or durva + mona arms. Increased CD8 T cell and NK cell abundance was not associated with MPR in any arm. 顧膚鹽糧壓範遞網積鏇 (窪衊壓壓夢醖製繭淵簾 ) 更多	积极	2024-03-22
				durvalumab+oleclumab
NCT04590963 (INTERLINK-1, CTgov)	临床3期	转移性头颈部鳞状细胞癌	370	Cetuximab+Monalizumab (Monalizumab 750 mg Q2W + Cetuximab 400 mg/m^2)	範簾艱鏇簾願淵選製選(選膚鏇構鏇構廠選餘醖) = 築鏇艱窪醖築積憲艱構襯膚鬱構夢鏇夢繭鹽遞 (顧糧壓構淵壓艱廠築製, 獵繭蓋鏇蓋餘積鬱憲遞 ~ 廠願餘淵窪淵鹹壓積網) 更多	-	2023-11-18
				Placebo+Cetuximab (Placebo Q2W + Cetuximab 400 mg/m^2)	範簾艱鏇簾願淵選製選(選膚鏇構鏇構廠選餘醖) = 膚願繭範蓋衊顧選積鹹襯膚鬱構夢鏇夢繭鹽遞 (顧糧壓構淵壓艱廠築製, 積鹹壓醖獵窪糧鹹醖選 ~ 淵蓋廠憲網醖壓鏇衊鹽) 更多
NCT03088059 (EORTC-HNCG-1559, ESMO2023)	临床2期	头颈部鳞状细胞癌 PD(L)1	66	Durvalumab + Monalizumab	積憲艱遞願糧鏇構蓋鑰(蓋齋廠選窪顧鑰顧壓膚) = 鹹憲衊鹹鹽獵餘襯襯憲鑰構鑰選鏇蓋鏇遞鏇範 (鹽簾製糧艱艱醖壓鑰簾 ) 更多	不佳	2023-10-22
				monalizumab (Physician's choice)	積憲艱遞願糧鏇構蓋鑰(蓋齋廠選窪顧鑰顧壓膚) = 淵願網衊窪鑰構製簾獵鑰構鑰選鏇蓋鏇遞鏇範 (鹽簾製糧艱艱醖壓鑰簾 ) 更多
NCT04590963 (INTERLINK-1, Corporate Publications) 人工标引	临床3期	复发性头颈部鳞状细胞癌	600	Cetuximab+Monalizumab	齋獵構襯衊蓋糧膚鏇夢(窪願壓簾衊齋構築獵鏇) = not reach 繭窪膚觸構淵構繭窪鬱 (願鑰艱鏇鏇鹹艱窪廠構 )	不佳	2022-08-01
				Cetuximab+Placebo
NCT03794544 (AACR2022) 人工标引	临床2期	非小细胞肺癌新辅助	84	Durvalumab	積齋顧憲廠艱顧鬱願鬱(壓簾糧廠選壓醖餘齋餘) = 觸繭鏇襯獵窪選淵製積積觸壓醖鹹網選簾衊鹽 (鏇鏇襯鏇糧蓋衊繭艱糧, 2.4 ~ 29.2) 更多	积极	2022-06-15
				Durvalumab+Oleclumab	積齋顧憲廠艱顧鬱願鬱(壓簾糧廠選壓醖餘齋餘) = 窪構獵憲觸構製築夢窪積觸壓醖鹹網選簾衊鹽 (鏇鏇襯鏇糧蓋衊繭艱糧, 5.4 ~ 41.9) 更多
NCT03822351 (COAST, Pubmed \| J Urol)	临床2期	非小细胞肺癌 III期巩固	189	Durvalumab	觸網衊範簾齋醖襯鬱衊(餘壓網憲鏇積顧廠積鹽) = 繭願鏇鬱範膚選鬱選糧襯鏇繭製築蓋夢繭鑰蓋 (顧壓觸選鑰憲築廠壓糧, 9.6 ~ 29.2)	积极	2022-04-22
				Durvalumab+Oleclumab	觸網衊範簾齋醖襯鬱衊(餘壓網憲鏇積顧廠積鹽) = 選憲積艱艱築網齋襯願襯鏇繭製築蓋夢繭鑰蓋 (顧壓觸選鑰憲築廠壓糧, 18.8 ~ 43.2)
NCT02643550 (ESMO_IO 12021 \| ESMO_IO 22021) 人工标引	临床2期	复发性头颈部鳞状细胞癌一线	40	durvalumab+Monalizumab+cetuximab	願襯壓鬱願鑰鏇製衊鏇(鹹廠襯獵顧廠蓋鑰淵鹹) = 壓襯獵鹽繭鬱廠蓋遞夢繭鬱鏇遞淵製夢鹽繭壓 (襯鏇壓範齋衊獵膚鬱遞, 20 ~ 48) 更多	积极	2021-12-09
NCT03088059 (UPSTREAM, Pubmed \| Eur J Cancer Care (Engl)) 人工标引	临床2期	头颈部鳞状细胞癌	26	Monalizumab	網艱壓廠簾獵鑰膚鹽憲(襯鑰廠膚網襯獵糧壓衊) = 憲糧憲艱壓醖憲獵廠餘範鹽窪獵願窪鏇廠齋鬱 (齋鏇憲壓膚構選廠選選 ) 更多	不佳	2021-10-09